See the DrugPatentWatch profile for Cinqair
What does “Cinqair” efficacy (EoE) look like in eosinophilic esophagitis?
Cinqair is benralizumab, an anti–IL-5 receptor alpha (IL-5Rα) therapy. Eosinophilic esophagitis (EoE) is an eosinophil-driven disease, so users often search for whether Cinqair has evidence for improving EoE outcomes (such as reducing esophageal eosinophils, improving dysphagia, or improving endoscopic findings).
On the information provided here, there are no specific efficacy results for Cinqair in EoE to cite. If you can share the exact paper/trial name or the specific claim you saw (for example, an “EoE” subgroup or a dose used), I can help interpret it.
Is Cinqair approved for EoE, or is it being used off-label?
Because your question is specifically about “Cinqair eoe efficacy,” the key practical follow-up is whether benralizumab is approved for EoE in your region (approval determines whether efficacy data is tied to label indications). The details needed for an accurate answer (approval status and indication labeling) are not included in what I have here.
What EoE outcomes are usually used to judge efficacy?
When researchers and clinicians assess EoE response, they commonly look for:
- Histologic response (fewer eosinophils on biopsy)
- Symptom improvement (especially swallowing difficulty)
- Endoscopic improvement (mucosal appearance)
- Durability over time and reduction in need for rescue therapy
If you tell me which endpoints you’re focused on, I can explain how to read the efficacy results.
How to find the right efficacy evidence quickly
If you’re trying to locate efficacy data for benralizumab in EoE, the fastest path is to search for:
- “benralizumab eosinophilic esophagitis trial”
- the NCT number if you have it
- the paper author/year you’re referencing
If you paste a snippet or link (or the NCT number), I’ll summarize the trial’s results in plain language, including what improved, by how much, and how consistent the findings were.